LCM
XGN icon

Laurion Capital Management’s Exagen XGN Stock Holding History

Laurion Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$525K – 992
2021
Q1 		$525K Buy
+30,000
New +$535K ﹤0.01% 583
2019
Q4 		– Sell
-30,000
Closed -$465K – 1281
2019
Q3 		$465K Buy
+30,000
New +$484K ﹤0.01% 779

Other funds holding XGN

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Laurion Capital Management's XGN Position: Q2 2021 in Review

Laurion Capital Management sold out of Exagen (XGN) in Q2 2021, closing a stake of 30,000 shares — an estimated $525K sold.

Laurion Capital Management first reported a position in XGN in Q3 2019 and held it in 2 quarters. The position peaked at $525K in Q1 2021. 54 funds tracked by Wall St. Rank hold XGN as of Q2 2021.

  • Laurion Capital Management reported no remaining Exagen position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 30,000 Exagen shares in Q2 2021, an estimated $525K.
  • Laurion Capital Management first reported a position in Exagen in Q3 2019 and held it in 2 quarters.
  • Laurion Capital Management's Exagen position peaked at $525K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Exagen as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.